Steven B. Binder net worth and biography

Steven Binder Biography and Net Worth

CFO of MannKind

Steve brings more than 25 years of healthcare experience to MannKind, including leading financial operations at biopharmaceutical and medical technology companies. Since July 2017, he has guided MannKind’s financial strategy, setting us up for financial success so that we can help others truly thrive.

How he lives life more humann:
Steve can often be found golfing, mountain biking, hiking, Nordic skiing, and snowshoeing in and around the mountains of California.

What is Steven B. Binder's net worth?: The estimated net worth of Steven B. Binder is at least $3.18 million as of May 12th, 2026. Mr. Binder owns 808,008 shares of MannKind stock worth more than $3,183,552 as of June 21st. This net worth evaluation does not reflect any other investments that Mr. Binder may own. Learn More about Steven B. Binder's net worth.
How do I contact Steven B. Binder?: The corporate mailing address for Mr. Binder and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on Steven B. Binder's contact information.
Has Steven B. Binder been buying or selling shares of MannKind?: During the past quarter, Steven B. Binder has sold $55,732.60 of MannKind stock. Most recently, Steven B. Binder sold 16,940 shares of the business's stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $3.29, for a transaction totalling $55,732.60. Following the completion of the sale, the director now directly owns 808,008 shares of the company's stock, valued at $2,658,346.32. Learn More on Steven B. Binder's trading history.
Who are MannKind's active insiders?: MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), Sanjay Singh (Executive Vice President, Technical Operations), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.
Are insiders buying or selling shares of MannKind?: In the last twelve months, MannKind insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $259,000.00. In the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 420,930 shares worth more than $2,244,947.31. The most recent insider tranaction occured on May, 12th when Director Steven B Binder sold 16,940 shares worth more than $55,732.60. Insiders at MannKind own 2.6% of the company. Learn More about insider trades at MannKind.
Information on this page was last updated on 5/12/2026.

Steven B. Binder Insider Trading History at MannKind

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/12/2026	Sell	16,940	$3.29	$55,732.60	808,008
7/16/2025	Sell	75,367	$3.94	$296,945.98	830,508
6/10/2025	Sell	64,085	$4.00	$256,340.00	925,258
5/20/2025	Sell	12,078	$4.40	$53,143.20	989,343
5/13/2025	Sell	80,144	$4.69	$375,875.36	1,006,611
11/22/2024	Sell	67,536	$6.89	$465,323.04	1,075,026
11/15/2024	Sell	67,539	$6.76	$456,563.64	1,075,026
8/29/2024	Sell	5,055	$5.94	$30,026.70	1,075,026
7/16/2024	Sell	2,836	$5.93	$16,817.48	1,100,860
5/13/2024	Sell	3,618	$4.31	$15,593.58	845,967
5/24/2023	Sell	47,810	$4.67	$223,272.70	838,324
7/31/2022	Buy	791	$2.93	$2,317.63	728,997
1/31/2022	Buy	711	$3.17	$2,253.87
7/30/2021	Buy	748	$2.99	$2,236.52
1/31/2021	Buy	1,557	$1.33	$2,070.81	398,822
7/31/2020	Buy	1,522	$1.25	$1,902.50	33,265
1/31/2020	Buy	2,168	$0.95	$2,059.60	48,204
7/31/2019	Buy	2,139	$0.95	$2,032.05	46,036
1/31/2019	Buy	1,860	$1.07	$1,990.20	3,620
8/2/2018	Buy	1,760	$1.31	$2,305.60	1,760

Steven B. Binder Buying and Selling Activity at MannKind

MannKind Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Today's Range

Now: $3.94

$3.83

$4.02

50 Day Range

MA: $3.24

$2.56

$4.00

2 Week Range

Now: $3.94

$2.23

$6.51

Volume

16,622,102 shs

Average Volume

5,374,040 shs

Market Capitalization

$1.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13